NCT03258567 2026-04-08
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
25 trialsNCT04554914 2026-02-20
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
Phase 2 Recruiting
NCT07368153 2026-01-26
IDEP
University Hospital, Basel, Switzerland
Phase 2 Not yet recruiting
NCT02532452 2025-12-16
Third Party Viral Specific T-cells (VSTs)
Children's Hospital Medical Center, Cincinnati
Phase 2 Recruiting
NCT07261215 2025-12-03
Zuberitamab for EBV Infection Post-Allo-HSCT
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT04925544 2025-10-21
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Stanford University
Phase 2 Active not recruiting
NCT07138989 2025-08-24
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT03266653 2025-08-08
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
New York Medical College
Phase 2 Recruiting
NCT05011058 2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2 Terminated
NCT00001379 2025-06-19
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02875613 2024-08-28
Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
University of California, San Diego
Phase 2 Terminated
NCT00834093 2023-06-28
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01972035 2022-04-12
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
University of Minnesota
Phase 2 Completed
NCT02874651 2022-01-11
ADVANCE
Sun Yat-sen University
Phase 2 Terminated
NCT00000712 2021-11-04
A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT01094405 2021-07-28
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
Chinese University of Hong Kong
Phase 2 Completed
NCT00267865 2020-06-01
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01136395 2019-10-08
Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation
University of Giessen
Phase 2 Completed
NCT01964755 2019-09-23
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
University of Miami
Phase 2 Terminated
NCT02763254 2019-03-26
CIVIC
Cell Medica Ltd
Phase 2 Terminated
NCT01948180 2019-03-13
CITADEL
Cell Medica Ltd
Phase 2 Terminated
NCT02269943 2018-12-12
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Celgene
Phase 2 Completed
NCT01058239 2018-02-15
Bortezomib Plus Rituximab for EBV+ PTLD
Massachusetts General Hospital
Phase 2 Completed
NCT00953420 2017-08-18
CADEN
Baylor College of Medicine
Phase 2 Completed
NCT00430534 2007-02-02
Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).
Henogen
Phase 2 Completed